BCL2 and diffuse large B-cell lymphoma: In this work, we elucidated anopportunity for therapeutic synergy in DLBCL by reactivating tumorprotein p53 with a stapled peptide, ATSP-7041, thereby priming cellsfor apoptosis and enhancing their sensitivity to BCL-2 family modulationwith a BH3-mimetic, ABT-263 (navitoclax).